|
PMID
|
Match String
|
Actual String
|
Score
|
Flanking text
|
Edited by
|
Edit
|
| 16104843 | VEGFR | VEGFRs | 3.0 | is the VEGF (vascular vascular endothelial growth factor family and VEGFRs (VEGF VEGF receptors | |  |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-1 also known as Flt-1 (Fms-like Fms-like tyrosine kinase-1 and VEGFR-2 also known as Flk-1 (fetal fetal liver kinase-1 and in | | |
| 16104843 | FLK1 | Flk-1 | 3.0 | Flt-1 (Fms-like Fms-like tyrosine kinase-1 and VEGFR-2 also known as Flk-1 (fetal fetal liver kinase-1 and in humans as KDR (kinase | | |
| 16104843 | KDR | KDR | 3.0 | as Flk-1 (fetal fetal liver kinase-1 and in humans as KDR (kinase kinase insert domain-containing receptor 3-5 | | |
| 16104843 | VEGFR | VEGFR | 3.3 | functions and the precise molecular mechanisms of the VEGF/VEGFR VEGF VEGFR system | | |
| 16104843 | VEGFR | VEGFR | 3.3 | recent advances in the basic biology of the VEGF/VEGFR VEGF VEGFR system which give insight into many physiological and pathological conditions | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | b is an endogenous inhibitory form of VEGF which binds VEGFR-2 with the same affinity as VEGF 165 but does not | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | PlGF binds VEGFR-1 but not VEGFR-2 35 36 | | |
| 16104843 | VEGFR | VEGFR | 3.3 | bind and activate VEGFR-3 (Flt-4; Flt-4 a member of the VEGFR family that does not bind VEGF-A as well as VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR family that does not bind VEGF-A as well as VEGFR-2 and are mitogenic for cultured endothelial cells | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | the fully processed form with a high affinity for both VEGFR-2 and VEGFR-3 49 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | All VEGF-E variants studied bind and activate VEGFR-2 but not VEGFR-1 or VEGFR-3 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Vammin does not bind VEGFR-1 but binds VEGFR-2 with high affinity as well as VEGF 165 64 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | However Tf svVEGF binds VEGFR-1 with high affinity and VEGFR-2 with low affinity compared with VEGF 165 leading to a | | |
| 16104843 | VEGFR | VEGFRs | 3.0 | VEGFRs | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-1 binds VEGF-A with at least 10-fold higher affinity than VEGFR-2 ( K d =10-30 pM 16 however ligand binding results | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | In many cases the effects of VEGFR-2 on endothelial cells such as those on cell survival and | | |
| 16104843 | VEGFR | VEGFR-1-blocking | 3.0 | VEGFR-1-blocking antibodies prevent the migration but not proliferation of HUVECs (human | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | of actin via p38 MAPK (mitogen-activated mitogen-activated protein kinase whereas VEGFR-2 contributes to the re-organization of the cytoskeleton by phosphorylating FAK | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGF-A from signalling receptors and by forming non-signalling heterodimers with VEGFR-2 69 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 is a 200-230 kDa high-affinity receptor for VEGF-A ( K | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 is expressed in vascular and lymphatic endothelial cells and other | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Tyrosine phosphorylation sites in human VEGFR-2 bound to VEGF-A are Tyr and Tyr in the kinase-insert | | |
| 16104843 | VEGFR | VEGFR-associated | 3.5 | Tyr creates a binding site for the VEGFR-associated protein 77 and Tyr creates a binding site for Sck | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 is the major mediator of the mitogenic angiogenic and permeability-enhancing | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Furthermore recent studies have indicated that the activation of VEGFR-2 also promotes lymphangiogenesis 80 81 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Survival signalling for endothelial cells from VEGFR-2 is reported to involve the PI3K (phosphoinositide phosphoinositide 3-kinase)/Akt 3-kinase | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | may be involved since the signal to activate PI3K by VEGFR-2 is usually not very strong | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Byzova et al 84 have reported that the activation of VEGFR-2 by VEGF-A results in the PI3K/Akt-dependent PI3K Akt-dependent activation of | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | synergic interaction with integrins is required for productive signalling from VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Very recently a naturally occurring soluble truncated form of VEGFR-2 has been detected in mouse and human plasma 85 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Similar to sVEGFR-1 sVEGFR-2 (soluble soluble VEGFR-2 may have regulatory consequences with respect to VEGF-mediated angiogenesis | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Unlike VEGFR-1 and VEGFR-2 VEGFR-3 is proteolytically cleaved within the fifth extracellular Ig loop | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGF 165 -induced proliferation and migration of cells that express VEGFR-2 are enhanced in the presence of NRP-1 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Thus NRP-1 also seems to function as an enhancer of VEGFR-2 activity in the presence of VEGF 165 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | is the result of the formation of a complex between VEGFR-2 and NRP-1 93 94 | | |
| 16104843 | VEGFR | VEGFR | 3.3 | VEGF/VEGFR VEGF VEGFR SYSTEM IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Homozygous loss of the VEGFR-1 or VEGFR-2 gene results in embryonic lethality between days 8.5 and 9.5 | | |
| 16104843 | VEGFR | VEGFRs | 3.0 | embryonic lethality between days 8.5 and 9.5 indicating that these VEGFRs play important roles in vasculogenesis and angiogenesis 101 102 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 mice die due to a lack of endothelial cell growth | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | the tyrosine kinase domain of VEGFR-1 103 has indicated that VEGFR-2 is the major positive signal transducer whereas VEGFR-1 has a | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Tyr and Tyr are two major VEGF-A-dependent autophosphorylation sites in VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | An unusual feature of mitogenic signalling from VEGFR-2 is the requirement for PKC but not Ras 104 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | knockin mice substituting Tyr (corresponding corresponding to Tyr in human VEGFR-2 and Tyr (Tyr Tyr in human of the VEGFR-2 gene | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | human VEGFR-2 and Tyr (Tyr Tyr in human of the VEGFR-2 gene with phenylalanine has revealed that the signalling via Tyr | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | with phenylalanine has revealed that the signalling via Tyr of VEGFR-2 is essential for endothelial and haematopoietic development during embryogenesis | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | the PI3K/p70 PI3K p70 S6K (S6 S6 kinase pathway by VEGFR-2 is also involved in VEGF-A-induced endothelial cell proliferation 107 ( | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGF-A increases vascular permeability in mesenteric microvessels by activation of VEGFR-2 on endothelial cells and subsequent activation of PLC | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Other studies have also demonstrated the crucial role of VEGFR-2 signalling in the enhancement of vascular permeability however our recent | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | the proliferation of endothelial cells under some active signalling from VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | blockade of Src prevents the disassociation of a complex comprising VEGFR-2 VE-cadherin and b -catenin with the same kinetics with which | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | enhancement of vascular permeability through the disruption of the VEGFR-2/cadherin/catenin VEGFR-2 cadherin catenin complex | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | hypothesis capturing of VEGF or blocking of its signalling receptor VEGFR-2 by a VEGFR tyrosine kinase inhibitor antisense oligonucleotides vaccination or | | |
| 16104843 | VEGFR | VEGFR | 3.3 | VEGF or blocking of its signalling receptor VEGFR-2 by a VEGFR tyrosine kinase inhibitor antisense oligonucleotides vaccination or neutralizing antibodies reduced | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | that PlGF regulates inter- and intra-molecular cross-talk between VEGFR-1 and VEGFR-2 amplifying VEGF-driven angiogenesis through VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | intra-molecular cross-talk between VEGFR-1 and VEGFR-2 amplifying VEGF-driven angiogenesis through VEGFR-2 | | |
| 16104843 | VEGFR | VEGFRs | 3.0 | VEGF-A and VEGFRs are constitutively expressed in the islet vasculature before and after | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | Pharmacological blockade of VEGFR-2 stabilizes the endothelial barrier function and suppresses tumour cell extravasation | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | tumour cell extravasation in vivo 136 suggesting the importance of VEGFR-2 signalling in this kind of tumour invasion and metastasis | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | 165 promotes survival of motor neurons during hypoxia through binding VEGFR-2 and NRP-1 161 | | |
| 16104843 | VEGFR | VEGFR | 3.3 | evidence has revealed that the role of the VEGF/VEGFR VEGF VEGFR system extends far beyond previous expectations | | |
| 16104843 | VEGFR | VEGFRs | 3.0 | Secondly several different VEGFRs have been shown to be essential but the interaction between | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | signal transducer in some cases individually and sometimes synergistically with VEGFR-2 via the intra- and inter-molecular cross-talk between these two receptors | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | An association between VEGFR-2 and VEGFR-3 has also been reported 166 | | |
| 16104843 | VEGFR | VEGFR | 3.3 | Thirdly it has been shown that the VEGF/VEGFR VEGF VEGFR system has multiple functions such as the induction of tumour | | |
| 16104843 | VEGFR | VEGFR | 3.3 | molecules have been found to associate with the VEGF/VEGFR VEGF VEGFR system | | |
| 16104843 | VEGFR | VEGFR | 3.3 | required to achieve a comprehensive understanding of the VEGF/VEGFR VEGF VEGFR system however the recent progress in the molecular and biological | | |
| 16104843 | VEGFR | VEGFR | 3.3 | type 2 UTR untranslated region VEGF vascular endothelial growth factor VEGFR VEGF receptor sVEGFR-1 soluble VEGFR-1 svVEGF snake venom VEGF Tf | | |
| 16104843 | VEGFR | VEGFR | 3.3 | VEGF-A binds to and activates two tyrosine kinase receptors VEGFR (VEGF VEGF receptor -1 and VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | two tyrosine kinase receptors VEGFR (VEGF VEGF receptor -1 and VEGFR-2 | | |
| 16104843 | VEGFR2 | VEGFR-2 | 4.3 | VEGFR-2 mediates most of the endothelial growth and survival signals but | | |
| 16104843 | VEGFR | VEGFR | 3.3 | in the molecular and biological understanding of the VEGF/VEGFR VEGF VEGFR system provides us with novel and promising therapeutic strategies and | | |